Integrated multi‐omics profiling of high‐grade estrogen receptor‐positive, HER2‐negative breast cancer

Estrogen receptor‐positive and human epidermal growth factor receptor 2‐negative (ER(+)HER2(−)) breast cancer accounts for ~ 60–70% of all cases of invasive breast carcinoma. High‐grade ER(+)HER2(−) tumors respond poorly to endocrine therapy. In this study, we systematically analyzed clinical and mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kang, Li, Lun, Franch‐Expósito, Sebastià, Le, Xin, Tang, Jun, Li, Qing, Wu, Qianxue, Bassaganyas, Laia, Camps, Jordi, Zhang, Xiang, Li, Hongyuan, Foukakis, Theodoros, Xiang, Tingxiu, Wu, Jiong, Ren, Guosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208078/
https://www.ncbi.nlm.nih.gov/pubmed/34146382
http://dx.doi.org/10.1002/1878-0261.13043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208078/
https://www.ncbi.nlm.nih.gov/pubmed/34146382
http://dx.doi.org/10.1002/1878-0261.13043

Ejemplares similares